{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PSI-7977+%28GS7977%29&page=2", "query": { "intervention": "PSI-7977 (GS7977)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 25, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PSI-7977+%28GS7977%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PSI-7977+%28GS7977%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T15:08:46.662Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01054729", "title": "Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "PEG", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 64, "start_date": "2010-01", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2014-04-17", "last_synced_at": "2026-09-30T15:08:46.662Z", "location_count": 6, "location_summary": "San Francisco, California • Gainesville, Florida • Orlando, Florida + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01054729" }, { "nct_id": "NCT01858766", "title": "Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "SOF", "type": "DRUG" }, { "name": "VEL", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 379, "start_date": "2013-04", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-09-30T15:08:46.662Z", "location_count": 50, "location_summary": "La Jolla, California • Long Beach, California • Los Angeles, California + 38 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01858766" }, { "nct_id": "NCT01559844", "title": "Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2012-03", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2016-07-27", "last_synced_at": "2026-09-30T15:08:46.662Z", "location_count": 13, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01559844" }, { "nct_id": "NCT01909804", "title": "Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "SOF", "type": "DRUG" }, { "name": "VEL", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 323, "start_date": "2013-06", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2018-11-15", "last_synced_at": "2026-09-30T15:08:46.662Z", "location_count": 40, "location_summary": "Long Beach, California • Los Angeles, California • Pasadena, California + 37 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01909804" }, { "nct_id": "NCT01687270", "title": "Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Chronic Hepatitis C Virus", "Post Liver Transplant" ], "interventions": [ { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2012-11", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2014-12-19", "last_synced_at": "2026-09-30T15:08:46.662Z", "location_count": 8, "location_summary": "San Francisco, California • Indianapolis, Indiana • Kansas City, Kansas + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01687270" }, { "nct_id": "NCT02292706", "title": "A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "LDV/SOF", "type": "DRUG" }, { "name": "SOF/VEL", "type": "DRUG" }, { "name": "SOF/VEL/VOX", "type": "DRUG" }, { "name": "Other SOF-Based Regimen", "type": "DRUG" }, { "name": "Ineligible parent treatment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1609, "start_date": "2014-12-29", "completion_date": "2021-12-31", "has_results": true, "last_update_posted_date": "2023-10-04", "last_synced_at": "2026-09-30T15:08:46.662Z", "location_count": 77, "location_summary": "Birmingham, Alabama • La Jolla, California • Long Beach, California + 57 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02292706" }, { "nct_id": "NCT01641640", "title": "Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" }, { "name": "PEG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 328, "start_date": "2012-06", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2014-05-08", "last_synced_at": "2026-09-30T15:08:46.662Z", "location_count": 55, "location_summary": "Birmingham, Alabama • Coronado, California • Los Angeles, California + 43 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Coronado", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01641640" }, { "nct_id": "NCT02201953", "title": "Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "SOF/VEL", "type": "DRUG" }, { "name": "SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 558, "start_date": "2014-07", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-09-30T15:08:46.662Z", "location_count": 25, "location_summary": "Los Angeles, California • Sacramento, California • San Diego, California + 21 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02201953" }, { "nct_id": "NCT01962441", "title": "SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" }, { "name": "Peg-IFN", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 601, "start_date": "2013-09-24", "completion_date": "2016-07-07", "has_results": true, "last_update_posted_date": "2017-06-20", "last_synced_at": "2026-09-30T15:08:46.662Z", "location_count": 23, "location_summary": "Riverside, California • San Diego, California • San Francisco, California + 19 more", "locations": [ { "city": "Riverside", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01962441" }, { "nct_id": "NCT01808248", "title": "Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "SOF", "type": "DRUG" }, { "name": "PEG", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2013-02", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2014-09-12", "last_synced_at": "2026-09-30T15:08:46.662Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01808248" } ] }